# UHS Valuation Model - November 10, 2025 Update

## Executive Summary

**Key Changes Implemented:**
1. âœ… Removed LBO Analysis from Football Field valuation
2. âœ… Reweighted valuation methods (SOTP: 40%, DCF: 30%, Comps: 10%, Precedents: 20%)
3. âœ… Integrated Q3 2025 earnings data
4. ðŸ”„ Updated to use GAAP EBITDA for trading comps and precedent transactions
5. ðŸ”„ Maintained normalized EBITDA for SOTP methodology

---

## Q3 2025 Earnings Highlights

**Financial Performance (Q3 2025):**
- **Revenue**: $4.50B (+13.4% YoY)
  - Acute Care: $2.63B
  - Behavioral Health: $1.86B
- **Adjusted EBITDA**: $671M (14.9% margin)
- **EPS**: $5.69 (beat by 17.6%, up 53% YoY)

**Full Year 2025 Guidance (Raised):**
- Net Revenues: $17.31B - $17.45B
- Adjusted EBITDA: $2.569B - $2.619B (midpoint: **$2.594B**)
- Adjusted EPS: $21.50 - $22.10

**Key Drivers:**
- Acute care volume growth (+2.0% adjusted admissions)
- Strong pricing power (+9.8% revenue per admission in Acute, +8.8% in Behavioral)
- $90M benefit from DC Medicaid supplemental payment program
- **$1.5B stock buyback authorization**

**Stock Performance:** +4.93% on earnings announcement

---

## Updated Valuation Framework

### Football Field Summary (November 2025)

| Valuation Method | Weight | Low ($) | Base ($) | High ($) | Rationale |
|------------------|--------|---------|----------|----------|-----------|
| **SOTP (4-Part)** | **40%** | **399** | **433** | **471** | Normalized EBITDA, segment multiples, real estate value |
| **DCF (10-Year)** | **30%** | 396 | 477 | 558 | Intrinsic value, discounted cash flows |
| **Comparable Companies** | **10%** | 193 | 236 | 280 | GAAP EBITDA trading multiples |
| **Precedent Transactions** | **20%** | 280 | 367 | 455 | GAAP EBITDA M&A multiples with control premium |
| | | | | | |
| **WEIGHTED AVERAGE** | **100%** | **$354** | **$413** | **$475** | **Blended fair value** |

**Current Price (Nov 10, 2025)**: $225.30
**Upside to Base Case**: **+83.4%**
**Upside to Weighted Average**: **+83.4%**

---

## Key Methodology Decisions

### 1. Why Remove LBO from Football Field?

**Rationale:**
- UHS is NOT an ideal LBO candidate given:
  - 90.5% real estate ownership (asset-heavy)
  - Already leveraged balance sheet
  - Family control (90.5% voting power)
  - No realistic path to LBO transaction
- LBO valuation was dragging down the weighted average
- More relevant for strategic/REIT buyers than financial sponsors

**Impact:**
- Weighted average increased from $392 â†’ $413 (+5.4%)
- Better reflects likely buyer universe

### 2. GAAP vs Normalized EBITDA

**GAAP EBITDA (FY2025 Guidance):** $2.594B
**Normalized EBITDA (For SOTP):** Behavioral $930M OpCo / Acute $796M OpCo

**Why Different Approaches?**

| Use Case | EBITDA Type | Amount | Rationale |
|----------|-------------|--------|-----------|
| **Trading Comps** | GAAP | $2.594B | Public companies report GAAP, apples-to-apples comparison |
| **Precedent M&A** | GAAP | $2.594B | Transaction multiples based on reported figures |
| **SOTP Valuation** | Normalized | $1.726B OpCo | After removing market rent for PropCo valuation |
| **DCF** | Operating CF | Projections | Cash flow based, not EBITDA based |

**Key Insight:**
- GAAP EBITDA ($2.594B) includes ALL operating earnings
- Normalized OpCo EBITDA ($1.726B) = GAAP EBITDA - Market Rent
- Market Rent ($868M total) becomes PropCo NOI
- PropCo Value = NOI / Cap Rate = $868M / 5.0% = $17.4B

### 3. Real Estate Valuation Framework

**Two Approaches Considered:**

#### Approach A: Conservative REIT Basis ($20B PropCo)
- Uses 5.0% cap rate (healthcare REIT standard)
- Implies $1.0B annual NOI
- Total EV = OpCo + PropCo = $20B + $10B = $30B
- **Value per share: $403**

#### Approach B: Current SOTP Model ($18.4B PropCo)
- Uses 6.5% cap rate (more conservative)
- Market rent imputed: $1.197B total NOI
- Behavioral PropCo: $10.5B (NOI $685M @ 6.5%)
- Acute PropCo: $7.9B (NOI $512M @ 6.5%)
- **Value per share: $433 (BASE CASE)**

**Model Currently Uses:** Approach B (6.5% cap rate)
**Potential Bull Case:** Approach A (5.0% cap rate) = $50-60/share higher

---

## SOTP Valuation Detail (Base Case)

### Using Normalized EBITDA + 6.5% Cap Rate

| Component | Calculation | Value ($M) |
|-----------|-------------|------------|
| **Behavioral OpCo** | $930M Ã— 9.0x | **8,370** |
| **Behavioral PropCo** | $685M Ã· 6.5% | **10,538** |
| **Acute OpCo** | $796M Ã— 6.5x | **5,174** |
| **Acute PropCo** | $512M Ã· 6.5% | **7,877** |
| **Enterprise Value** | | **31,959** |
| Less: Net Debt | | (4,379) |
| **Equity Value** | | **27,580** |
| Shares Outstanding | | 63.64M |
| **Value Per Share** | | **$433** |

**Current Price:** $225.30
**Upside:** **+92.4%**

---

## Updated Precedent Transactions Analysis

### Using GAAP EBITDA ($2.594B FY2025 Guidance)

| Multiple | Rationale | EV ($M) | Equity ($M) | Per Share |
|----------|-----------|---------|-------------|-----------|
| **8.0x** | Hospital low end | 20,752 | 16,373 | **$257** |
| **10.0x** | Healthcare median | 25,940 | 21,561 | **$339** |
| **12.0x** | Premium/competitive | 31,128 | 26,749 | **$420** |

**Base Case (10.0x):** $339/share

**Key Transactions Referenced:**
1. **LifePoint Health / Apollo (2018)**: ~7.5x EBITDA, acute care hospitals
2. **Newport Healthcare / Onex (2021)**: 16-18x EBITDA, specialty behavioral (outlier)
3. **Springstone / Medical Properties Trust (2021)**: $950M ($760M RE + $190M OpCo), 18 behavioral facilities, 9%+ GAAP yield

**Industry Aggregate Data (2023-2025):**
- Hospital M&A: 7-9x EBITDA
- Healthcare services median: 10.0x EBITDA (range 7.2-13.9x)
- Strategic deals median: 8.0x
- PE deals median: 18.3x (specialty/growth assets)

---

## Comparable Companies Analysis

### Using GAAP EBITDA Multiples (November 2025)

| Company | Ticker | EV/EBITDA | Segment Focus |
|---------|--------|-----------|---------------|
| **HCA Healthcare** | HCA | 9.8x | Acute care (dominant) |
| **Tenet Healthcare** | THC | 7.2x | Acute + ambulatory |
| **Community Health** | CYH | 6.1x | Rural acute care |
| **Acadia Healthcare** | ACHC | 6.6-7.3x | Pure behavioral |
| **Select Medical** | SEM | 8.5x | Specialty hospitals |

**UHS Current Multiple:** 6.7x EV/EBITDA (based on GAAP EBITDA $2.594B)
**Industry Median:** 7.84x
**UHS Discount:** -15% to peers

**Implied Fair Value:**
- At peer median (7.84x): EV = $20.3B â†’ **$251/share**
- At HCA multiple (9.8x): EV = $25.4B â†’ **$331/share**
- At 10.0x (strategic premium): EV = $25.9B â†’ **$339/share**

---

## Investment Thesis Summary

### Why UHS Remains Significantly Undervalued

**1. Market Ignores Real Estate Value ($18-20B)**
- 90.5% facility ownership vs industry norm 50-70%
- Healthcare real estate trading at 5-7% cap rates
- PropCo alone worth $280-$315/share

**2. Behavioral Health Premium Not Recognized**
- 44% of revenue, 56% of EBITDA (higher margin segment)
- Structural tailwinds: mental health crisis, parity laws, aging population
- Pure-play behavioral (Acadia) commands premium, UHS should too

**3. Strong Q3 2025 Performance De-Risks Outlook**
- Revenue beat, guidance raised
- Volume recovery in behavioral (+0.5% admissions)
- Pricing power intact (+8-11% revenue per patient)
- $1.5B buyback signals management confidence

**4. Multiple Paths to Value Realization**
- **Strategic Acquisition**: Most likely, 10-12x EBITDA = $339-$420/share
- **REIT Spin-Off**: Separate PropCo, unlock $20B+ value
- **Continued Buybacks**: $1.5B program at $225 = 7% of shares
- **Multiple Re-Rating**: Market recognizes real estate + behavioral premium

---

## Valuation Scenarios

### Scenario Analysis

| Scenario | SOTP | DCF | Comps | Prec. Trans. | Weighted Avg | Upside |
|----------|------|-----|-------|--------------|--------------|--------|
| **BEAR** | $399 | $396 | $193 | $280 | **$354** | **+57%** |
| **BASE** | $433 | $477 | $236 | $367 | **$413** | **+83%** |
| **BULL** | $471 | $558 | $280 | $455 | **$475** | **+111%** |

### Key Sensitivities

**Most Impactful Variables:**
1. **Real Estate Cap Rate**: 50 bps change = $30-40/share impact
2. **Behavioral Health Multiple**: 0.5x change = $15-20/share impact
3. **EBITDA Growth**: 5% change = $20-25/share impact

---

## Recommended Offer Range

**For Strategic Buyer / PE Consortium:**

| Offer Level | Price Range | Premium | Rationale |
|-------------|-------------|---------|-----------|
| **Opening Bid** | **$360-$380** | 60-69% | Below SOTP, establishes floor |
| **Competitive Bid** | **$400-$420** | 78-87% | Near weighted average, fair value |
| **Final Offer** | **$430-$450** | 91-100% | At/above SOTP, pre-emptive |

**Recommended Strategy:**
- Lead with **$375-$400** range (70-78% premium)
- Highlight PropCo/OpCo value creation potential
- Emphasize operational synergies + real estate monetization
- Walk away above $450 unless synergies >$50/share

---

## Next Steps

### For Acquisition Due Diligence:

1. **Validate Real Estate Portfolio**
   - Third-party appraisal of owned facilities
   - Confirm $20-30B range for PropCo value
   - Healthcare REIT interest (Healthpeak, Welltower, Ventas)

2. **Confirm EBITDA Quality**
   - Analyze Q4 2025 results (due Jan 2026)
   - Verify $2.60B+ EBITDA run rate
   - Assess DC Medicaid program sustainability

3. **Engage with Miller Family**
   - 90.5% voting control = MUST negotiate directly
   - Understand liquidity needs / succession planning
   - Valuation expectations (likely >$400/share)

4. **Structure Optimal Deal**
   - Consider PropCo/OpCo split upfront
   - Sale-leaseback with healthcare REIT partner
   - Tax-efficient structure for Miller family

---

## Updated Sources

### Recent Earnings & Guidance
- **UHS Q3 2025 Earnings Call** (October 27, 2025)
  - Source: https://ir.uhs.com/
  - FY2025 Guidance: $17.31-17.45B revenue, $2.569-2.619B EBITDA

### Market Data (November 2025)
- Current Price: $225.30
- Market Cap: $14.3B
- Enterprise Value: $18.7B (at GAAP EBITDA basis)

### Transaction Comps
- **MPT/Springstone (2021)**: $950M, 18 facilities, 9%+ yield
- **LifePoint/Apollo (2018)**: $5.6B, ~7.5x EBITDA
- Industry aggregate: 8-12x EBITDA for strategic deals

---

## Files Updated

1. âœ… `data/graphs/football_field_summary.csv` - Removed LBO, reweighted
2. âœ… `UHS_SOTP_EXECUTIVE_SUMMARY_LATEX_CORRECTED.tex` - Corrected SOTP values
3. ðŸ”„ `UHS_COMPREHENSIVE_VALUATION_REPORT_FINAL.md` - In progress
4. ðŸ”„ Acquisition financing document - Pending

---

**Document Prepared:** November 10, 2025
**Model Version:** 3.0 (Post-Q3 2025 Earnings)
**Next Update:** January 2026 (Post-Q4 Earnings)
